Diabetic Polyneuropathy
Conditions
Keywords
Glycosylated hemoglobin, Nerve conduction studies, Diabetic polyneuropathy, Spatiotemporal gait parameters., Type II DM
Brief summary
This study will be conducted to investigate the relationship between glycosylated hemoglobin (HbA1c) and nerve conduction studies (NCS) with gait performance in patients with DPN. 65 patients with type II DM with moderate polyneuropathy will participate in this study. Glycosylated Hemoglobin (HbA1c) test will be done for each patient by using the Colorimeter device. Nerve conduction studies (NCS) will be performed for each patient by using the electromyography device to confirm the diagnosis of DPN. The neurophysiological functions of peripheral nerves including (The Common peroneal, Tibial, Sural, and Ulnar motor & sensory branches) will be measured. Spatiotemporal gait parameters (stride length, cadence& velocity) for all the patients will be assessed by two-dimension video-based motion analysis (2D).
Detailed description
The current study is to investigate the correlation between glycosylated haemoglobin (HbA1c) with nerve conduction studies (NCS) including amplitudes, conduction velocities &latency with spatiotemporal gait parameters including stride length, cadence& velocity in patients with diabetic polyneuropathy (DPN). The patients will be recruited from the Out- patient clinic of Faculty of Physical Therapy, Cairo University. All the patients suffering from moderate polyneuropathy according to Toronto Clinical Neuropathy Scoring System (TCSS), and Neuropathy Impairment Score in the lower limbs (NIS-LL). Glycosylated Hemoglobin (HbA1c) test will be done for each patient by using the Colorimeter device. Blood will be collected in a EDTA (3 cm) tube that's attached to the needle. A nerve conduction study will be performed for each patient. Five nerves will be examined in this study including (The common peroneal, tibial, sural and ulnar motor & sensory branches). The Nerve conduction studies involve analysis of specific parameters including amplitude (mv), latency (msec.) and conduction velocity(m/s). The evaluation procedure will be explained to each patient before starting examination. Gait parameters including (stride length, cadence & velocity) will be assessed using 2D video-based motion analysis. The gait will be captured by a digital video camera; (Canon 10 mega pixel - 4x optical zoom, lens 4x15/6.2-24.8mm1:2.7-5.6). The resultant captured film will then be processed using a special software computer program (Adobe premier ver. 6.0).
Interventions
None listed
Sponsors
Shereen Saad Eldin Mohamed Ali
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
40 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* The diagnosis will be confirmed by Nerve Conduction Studies NCS. * All the patients suffering from moderate polyneuropathy according to Toronto Clinical Neuropathy Scoring System (TCSS) and Neuropathy Impairment Score (NIS-LL). * Body mass index (BMI) will range from 20:30 kg/m2. * Age will range from 40-60 years. * Postprandial blood sugar more than 200 mg/dl. * Duration of diabetic illness five years ago or more and serum Hb1AC will be between 7% and 14%. * Able to walk independently with or without walking aids.
Exclusion criteria
* Patients with type I DM. * History of myopathy or neuromuscular diseases. * Pregnant females. * Alcoholics. * History of major cardiac diseases, heavy metal. * Other neurological problems as stroke. * History of ulcers in the lower limbs, foot deformities or malunion fracture of the lower limbs, and acute nerve root compression or advanced arthritis affecting lower extremity.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The neurophysiological parameters | At baseline for all patients | Five nerves will be examined in this study including (The common peroneal, tibial, sural and ulnar motor & sensory branches). Nerve conduction studies (NCS) will be performed by using the electromyography device. |
| Glycosylated Hemoglobin (HbA1c) level | At baseline for all patients | Glycosylated Hemoglobin (HbA1c) test will be done for each patient by using the Colorimeter device. The Blood will be collected in a EDTA (3 cm) tube |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Spatiotemporal gait parameters | At baseline for all patients | Spatiotemporal gait parameters for all the patients will be assessed by two-dimension video-based motion analysis (2D). |
Countries
Egypt
Contacts
Primary ContactHamada Ahmed Hamada, Assistant professor
Outcome results
None listed